الفهرس Only 14 pages are availabe for public view
 |  | from | 125 |  |  |
| | | from | 125 | | |
Abstract
Hepatocellular carcinoma (HCC) is the fifth common cancer worldwide and the third common cause of cancer mortality, and the third cause of cancer related death. HCC comprises more than 90% of human liver cancers. The incidence of HCC is increasing due to increased rates of hepatitis B and C viral infection.The utilization of a vailable biomarkers providing guidelines to facilitate preclinical research for the development of treatments for HCC patients.Cancer stem cells (CSCs) are the source of many solid tumor types, including hepatocellular carcinoma (HCC.CD90 (Thy-1) is a 25-37 kDa glycosylphosphatidylinositol GPI)- anchored glycoprotein with single V-like immunoglobulin domain expressed mainly in leukocytes, Thy-1 has speculated roles in cell-cell and cell-matrix interactions, nerve regeneration, metastasis,inflammation, and fibrosis.Thy-1 can be considered as a marker for various kind of stem cells, e.g. hematopoietic stem cells (HSCs), mesenchymal stem cells,bone marrow-derived mesenchymal stem cells,hepatic stem/progenitor cells (HSPCs). CD90 was expressed in most of the basal layer of the normal human epidermis.CD90 is considered as a phenotypic expression of Cancer stem cells. CD90+ cells in the hepatocellular carcinoma (HCC) have been shown to display tumorgenic capacity. The study included (30) patients, (15) of them were cirrhotic and the other (15) were HCC. (10) healthy volunteers with matched age and gender were enrolled in the study as a control group.All groups were subjected to full clinical examination, abdominal ultrasound, hepatitis viral markers (HBs Ag, HCV Abliver function tests, α-fetoprotein and, CD90 expression.